Navigation Links
Federal grant funds research on novel HIV therapy

An immunology researcher at The Children's Hospital of Philadelphia leads a multi-center $6.7 million program project grant recently awarded by the National Institute of Mental Health (NIMH) to explore a novel approach to HIV treatment.

Encompassing basic science research, animal studies and clinical trials in adult patients, the new grant focuses on a potential Achilles' heel in the human immunodeficiency virus: sites on immune cells known as neurokinin-1 receptors. In focusing on those sites, researchers hope to achieve a triple benefit: fighting HIV by blocking the virus from immune cells, improving innate immune function and reducing symptoms of depression that are associated with the disease.

Steven D. Douglas, M.D., professor of Pediatrics, chief of the Section of Immunology and director of Clinical Immunology Laboratories at The Children's Hospital of Philadelphia, is the principal investigator and program director of the new Integrated Preclinical/Clinical Program grant. Dr. Douglas oversees projects led by collaborators at four sites: Children's Hospital, the University of Pennsylvania, Tulane National Primate Research Center, and Seracare Bioservices, Inc.

The program project is entitled, "Neurokinin-1R (SP Receptor) Antagonists for HIV Therapy." NIMH, a member institute of the National Institutes of Health, issued the four-year, $6.7 million grant award this fall.

The grant builds on more than a decade of investigation by Dr. Douglas into substance P, a neurotransmitter long known to be active in the brain and nervous system. Dr. Douglas and colleagues discovered in 1997 that immune cells produce substance P and its receptor, neurokinin-1, and later showed that incubation with substance P raised HIV levels in immune cell cultures. They subsequently found that a compound that binds to the substance P receptor in immune cells inhibits HIV from entering its hiding place within immune cells.

That compound, from a class of agents called neurokinin-1 receptor antagonists, may represent a new type of anti-HIV therapy, due to its ability to block HIV replication. The new program project grant will allow researchers to explore the potential of neurokinin-1 receptor (NK-1R) antagonists in a variety of ways.

In addition to studying direct antiviral action, the researchers will also look for effects on behavior. Because NK-1R antagonists are known to have antidepressant properties, any evidence of reduced anxiety-related behavior in animals may suggest potential important benefits for human HIV patients as well.

The grant includes four separate projects. Projects 1 and 2, led by virologist Wen-Zhe Ho, M.D., of Children's Hospital, and Dr. Douglas, respectively, aim to better understand the underlying mechanisms behind anti-HIV activity of NK-1R antagonists. The basic science research will particularly examine how these agents affect HIV-infected immune cells and how they also might protect the brain. "We know that substance P plays an important role in both the immune system and the central nervous system," said Dr. Douglas, "and we are testing the hypothesis that interfering with substance P receptors may reduce neurological injury from HIV infection."

Project 3, led by Andrew A. Lackner, Ph.D., D.V.M., director of the Tulane National Primate Research Center, will test whether NK-1R antagonists are safe in animals infected with simian immunodeficiency virus (SIV), which is analogous to HIV. This study aims to provide proof of concept for human trials under Project 4.

Project 4, led by Pablo Tebas, M.D., of the Department of Medicine at the University of Pennsylvania Medical School, will be a phase 1 (safety) trial of the NK-1R antagonist aprepitant (trade name Emend) in adults with HIV infection. Aprepitant is currently used to control nausea caused by chemotherapy; this project will determine whether the antagonist may also attack HIV infection in pati ents.

The grant also includes a private sector collaborator, Seracare Bioservices, Inc., of Gaithersburg, Md., for whom the principal investigator is Janet L. Lathey, Ph.D. This core laboratory will test candidate NK-1R drugs in conjunction with existing HIV drugs, evaluating antiviral activity against HIV-infected cells. "Including a private sector partner is a way to strengthen the goal of moving our scientific studies closer to clinical application," said Dr. Douglas.

Finally, a Biostatistics and Pharmacology Core serves all other components of the project. Directed by Avital Cnaan, Ph.D., with co-director Jeffrey Barrett, Ph.D., both of Children's Hospital, this core seeks to define linkages among the basic science experiments, the animal model experiments to establish pharmacology responses and the human trials designed to assess safety and activity.

The basic science projects of this four-year grant are already providing data, building on existing investigations of NK-1R antagonists. The animal model studies and clinical trials are in their initial stages.
'"/>

Source:Children's Hospital of Philadelphia


Related biology news :

1. Federal testing for mad cow disease a failure, law review editor says
2. Researcher gets NSF grant to create mutant maize lines
3. MSU researchers receive $4 million grant to uncover gene functions
4. Virulizin granted orphan drug status in Europe
5. New NIAID grants strengthen national biodefense and emerging infectious diseases research network
6. Asian immigrants in NYC not receiving HIV education at religious institutions
7. Boston University biomedical engineers win major grant for pursuit of the $1,000 Genome
8. Scientists win grants to develop $1,000 genome sequencing technology
9. In presence of fragrant cleaning products, air purifiers that emit ozone can dirty the air
10. W.M. Keck Foundation funds study of friendly microbes
11. WHO suspends Marburg work, appeals for new funds

Post Your Comments:
*Name:
*Comment:
*Email:


(Date:4/28/2016)... 2016 First quarter 2016:   ... with the first quarter of 2015 The gross margin ... (loss: 18.8) and the operating margin was 40% (-13) ... Cash flow from operations was SEK 249.9 M (21.2) , ... unchanged, SEK 7,000-8,500 M. The operating margin for 2016 ...
(Date:4/26/2016)... -- Research and Markets has announced the ...  report to their offering.  , ,     (Logo: ... forecast the global multimodal biometrics market to grow ... 2016-2020.  Multimodal biometrics is being implemented ... healthcare, BFSI, transportation, automotive, and government for controlling ...
(Date:4/15/2016)... April 15, 2016  A new partnership announced ... accurate underwriting decisions in a fraction of the ... priced and high-value life insurance policies to consumers ... With Force Diagnostics, rapid testing (A1C, Cotinine ... readings (blood pressure, weight, pulse, BMI, and activity ...
Breaking Biology News(10 mins):
(Date:5/25/2016)... (PRWEB) , ... May 25, 2016 , ... Lajollacooks4u has ... and has consistently been rated one of its top attractions. Fortune 500 companies, ... to participate in a unique and intimate team-building experience. , Each event kicks off ...
(Date:5/25/2016)... ... May 25, 2016 , ... Founder of the Fitzmaurice Hand ... and surgery of the hand by the National Board of Physicians and Surgeons, ... and beyond in his pursuit of providing the most comprehensive, effective treatment for ...
(Date:5/25/2016)... ... May 25, 2016 , ... WEDI, the nation’s leading authority ... announced that Charles W. Stellar has been named by the WEDI Board of Directors ... 2016. As an executive leader with more than 35 years of experience in healthcare, ...
(Date:5/24/2016)... ... May 24, 2016 , ... Cell therapies ... will be accelerated by research at Worcester Polytechnic Institute (WPI) that yielded a ... and tissue regeneration. , The novel method, developed by WPI faculty members Raymond ...
Breaking Biology Technology: